<SEC-DOCUMENT>0001640334-17-002310-index.html : 20171106 <SEC-HEADER>0001640334-17-002310.hdr.sgml : 20171106 <ACCEPTANCE-DATETIME>20171106170512 ACCESSION NUMBER: 0001640334-17-002310 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171106 DATE AS OF CHANGE: 20171106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NYMOX PHARMACEUTICAL CORP CENTRAL INDEX KEY: 0001018735 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-12033 FILM NUMBER: 171180095 BUSINESS ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 BUSINESS PHONE: 1-800-936-9669 MAIL ADDRESS: STREET 1: 9900 CAVENDISH BLVD., SUITE 306 STREET 2: ST. LAURENT CITY: QUEBEC CANADA STATE: A8 ZIP: H4M 2V2 </SEC-HEADER> <DOCUMENT> <TYPE>6-K <SEQUENCE>1 <FILENAME>nymox_6k.htm <DESCRIPTION>FORM 6-K <TEXT> Document 1 - file: nymox_6k.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>2 <FILENAME>nymox_ex991.htm <DESCRIPTION>MANAGEMENT'S DISCUSSION AND ANALYSIS <TEXT> Document 2 - file: nymox_ex991.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.2 <SEQUENCE>3 <FILENAME>nymox_ex992.htm <DESCRIPTION>CEO CERTIFICATIONS <TEXT> Document 3 - file: nymox_ex992.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.3 <SEQUENCE>4 <FILENAME>nymox_ex993.htm <DESCRIPTION>CFO CERTIFICATIONS <TEXT> Document 4 - file: nymox_ex993.htm
</DOCUMENT> </SEC-DOCUMENT>